Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.45 |
| ▸ | CCR5 | P51681 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302101 | 0.94 | HTR4 (0.53) | HTR4CCR5OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL3297660 | 0.93 | HTR4 (0.52) | HTR4CCR5OPRM1OPRL1 | |
| SCHEMBL3300988 | 0.93 | HTR4 (0.52) | HTR4CCR5OPRM1OPRL1 | |
| SCHEMBL3301384 | 0.92 | HTR4 (0.49) | HTR4CCR5SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3301436 | 0.90 | OPRM1 (0.49) | HTR4CCR5OPRM1OPRL1 | |
| SCHEMBL2331638 | 0.88 | HTR4 (0.52) | HTR4SLC6A2SLC6A3SLC6A4OPRM1 | |
| SCHEMBL3298892 | 0.88 | HTR4 (0.56) | HTR4UTS2R | |
| SCHEMBL15103570 | 0.85 | HTR4 (0.49) | HTR4SLC6A2SLC6A3OPRM1OPRL1 | |
| SCHEMBL2335601 | 0.83 | HTR4 (0.55) | HTR4SLC6A2SLC6A3SLC6A4OPRM1 | |
| Hydrochloric Acid SCHEMBL3300209 | 0.82 | HTR4 (0.55) | HTR4SLC6A2SLC6A3SLC6A4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | claimed |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-15 | — | — | US | claimed |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2019-03-28 | — | — | US | disclosed |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-12-04 | — | — | US | disclosed |
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2017-09-28 | — | — | US | disclosed |
| US-9676718-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-06-13 | — | — | US | disclosed |
| US-9593102-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-03-14 | — | — | US | disclosed |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2016-12-15 | — | — | US | disclosed |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-05-15 | — | — | US | disclosed |
| US-8642772-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-02-04 | — | — | US | disclosed |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | SK HOLDINGS CO., LTD. (KR) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275250-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885UTS2R 1614/4885CCR5 728/4885 |
| US-10144709-B2 | Piperidine compounds, pharmaceutical composition comprising the same and its use | PGC, VIP, PIGO | HTR4 308/4885UTS2R 1614/4885CCR5 728/4885 |
| US-20190092727-A1 | Piperidine Compounds, Pharmaceutical Composition Comprising The Same And Its Use | PGC, VIP, PIGO | HTR4 308/4885UTS2R 1614/4885CCR5 728/4885 |
| US-20160362374-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885UTS2R 1614/4885CCR5 728/4885 |
| US-20100093801-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885UTS2R 1614/4885CCR5 728/4885 |
| US-20140135314-A1 | PIPERIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND ITS USE | PGC, VIP, PIGO | HTR4 308/4885UTS2R 1614/4885CCR5 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.